FOXC1 drives lung cancer metastasis and functions as a target for AI-enabled anti-metastatic drug discovery
Sisi Cao, Siqi Peng, Zijun Huang, Jinlan Deng, Jiayuan Wu, Mei Qin, Jianpeng Nong, Linhong He, Lin Liu, Meichun Qin, Lin Tao, Jing Lai, Wenkai Chen, Changyue Jiang, Jie Yang, Yingxin Li · 2026
Read FOXC1 drives lung cancer metastasis and functions as a target for AI-enabled anti-metastatic drug discovery by Sisi Cao, Siqi Peng, Zijun Huang, Jinlan Deng, Jiayuan Wu, Mei Qin, Jianpeng Nong, Linhong He, Lin Liu, Meichun Qin, Lin Tao, Jing Lai, Wenkai Chen, Changyue Jiang, Jie Yang, Yingxin Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13601247.txt.
Description
Sisi Cao and a large team target a gene that drives lung cancer spread. Their study from twenty twenty-six examines FOXC1 in metastatic disease. Spread, not the primary tumour, causes most lung cancer deaths. FOXC1 was known to promote cancer growth generally.
Metastatic samples carried higher FOXC1 levels than other tissue. The gene switches on a growth signal gene directly. That signal then feeds back to keep FOXC1 active. Cell and mouse tests confirmed the spread-promoting loop. An AI platform proposed compounds that bind the gene product. Binding tests and simulations checked the best candidates. A new anti-spread drug may grow from this target.
Catalog record
| CREATOR | Sisi Cao, Siqi Peng, Zijun Huang, Jinlan Deng, Jiayuan Wu, Mei Qin, Jianpeng Nong, Linhong He, Lin Liu, Meichun Qin, Lin Tao, Jing Lai, Wenkai Chen, Changyue Jiang, Jie Yang, Yingxin Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |